[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2023006290A - Derivados de 2,3-dihidro--benzo[b][1,4]oxazin-4-il)(5-(fenil)-piri din-3- il)metanona y compuestos similares como inhibidores de cyp11a1 para el tratamiento del cáncer de próstata. - Google Patents

Derivados de 2,3-dihidro--benzo[b][1,4]oxazin-4-il)(5-(fenil)-piri din-3- il)metanona y compuestos similares como inhibidores de cyp11a1 para el tratamiento del cáncer de próstata.

Info

Publication number
MX2023006290A
MX2023006290A MX2023006290A MX2023006290A MX2023006290A MX 2023006290 A MX2023006290 A MX 2023006290A MX 2023006290 A MX2023006290 A MX 2023006290A MX 2023006290 A MX2023006290 A MX 2023006290A MX 2023006290 A MX2023006290 A MX 2023006290A
Authority
MX
Mexico
Prior art keywords
sub
cyp11a1
inhibitors
treatment
prostate cancer
Prior art date
Application number
MX2023006290A
Other languages
English (en)
Inventor
Gerd Wohlfahrt
Belle David Din
Petteri Rummakko
Pekka Pietikäinen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MX2023006290A publication Critical patent/MX2023006290A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula (I) (ver fórmula) en donde A, B, C, L, Z, R1, R2, R3, R4 y R5 son como se definen en la reivindicación 1, o bien se revelan sales farmacéuticamente aceptables de los mismos. Los compuestos de la fórmula (I) o (II) poseen utilidad como inhibidores del citocromo P450 monooxigenasa 11A1 (CYP11A1). Los compuestos son útiles como medicamentos en el tratamiento de receptores de esteroides, por ejemplo, receptores de andrógenos o receptores de estrógenos, enfermedades y afecciones dependientes, como el cáncer de próstata y el cáncer de estrógenos.
MX2023006290A 2020-12-01 2021-11-30 Derivados de 2,3-dihidro--benzo[b][1,4]oxazin-4-il)(5-(fenil)-piri din-3- il)metanona y compuestos similares como inhibidores de cyp11a1 para el tratamiento del cáncer de próstata. MX2023006290A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20206226 2020-12-01
PCT/FI2021/050828 WO2022117920A1 (en) 2020-12-01 2021-11-30 2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as cyp11a1 inhibitors for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
MX2023006290A true MX2023006290A (es) 2023-08-21

Family

ID=78827916

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006290A MX2023006290A (es) 2020-12-01 2021-11-30 Derivados de 2,3-dihidro--benzo[b][1,4]oxazin-4-il)(5-(fenil)-piri din-3- il)metanona y compuestos similares como inhibidores de cyp11a1 para el tratamiento del cáncer de próstata.

Country Status (9)

Country Link
US (1) US20240124431A1 (es)
EP (1) EP4255902A1 (es)
JP (1) JP2023551340A (es)
KR (1) KR20230117187A (es)
CN (1) CN116724034A (es)
AU (1) AU2021391977A1 (es)
CA (1) CA3200556A1 (es)
MX (1) MX2023006290A (es)
WO (1) WO2022117920A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202409023A (zh) * 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
WO2024199262A1 (zh) * 2023-03-29 2024-10-03 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
WO2024217531A1 (zh) * 2023-04-21 2024-10-24 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110412A1 (es) 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1

Also Published As

Publication number Publication date
CA3200556A1 (en) 2021-11-30
JP2023551340A (ja) 2023-12-07
WO2022117920A1 (en) 2022-06-09
AU2021391977A9 (en) 2024-08-01
US20240124431A1 (en) 2024-04-18
CN116724034A (zh) 2023-09-08
KR20230117187A (ko) 2023-08-07
AU2021391977A1 (en) 2023-07-13
EP4255902A1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
MX2023006290A (es) Derivados de 2,3-dihidro--benzo[b][1,4]oxazin-4-il)(5-(fenil)-piri din-3- il)metanona y compuestos similares como inhibidores de cyp11a1 para el tratamiento del cáncer de próstata.
Cole et al. Mechanism and inhibition of cytochrome P-450 aromatase
AU2006218711B2 (en) Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
MXPA05010874A (es) Compuestos n-heterociclicos condensados y su uso como antagonistas del receptor del factor liberador de corticotropina.
AU2004257696B2 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
Moreira et al. Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors
HK1081958A1 (en) Thienopyridazinone derivative as modulators of autoimmune diseases
EA032467B1 (ru) Нестероидные антиандрогены и селективные модуляторы андрогеновых рецепторов с пиридильной группой
ZA200309708B (en) Hetero-bicyclic CRF antagonists.
IL97122A (en) 7-Transformed androstane-) or androstine- (3,71-dions, useful as aromatase inhibitors, and pharmaceuticals containing them
ZA202212150B (en) Tricyclic compounds as egfr inhibitors
PE20240217A1 (es) Preparacion de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
DE60226971D1 (de) Corticotropinfreisetzungsfaktor antagonisten
DE60144246D1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
WO2009083272A3 (de) 19-NOR-STEROIDDERIVATE MIT EINER 15α,16α-METHYLENGRUPPE UND EINEM GESÄTTIGTEN 17,17-SPIROLACTONRING, DEREN VERWENDUNG SOWIE DIESE DERIVATE ENTHALTENDE ARZNEIMITTEL
Numazawa et al. Structure–activity relationships of estrogen derivatives as aromatase inhibitors. Effects of heterocyclic substituents
MX2023004108A (es) Derivados de benzo[h]quinazolin-4-amina y tieno[3,2-h]quinazolin-4 -amina para el tratamiento del cáncer.
Sedighi et al. In vivo evaluation of the aromatase inhibition by 4‑((1H‑imidazol‑1‑yl) methyl)‑2‑(4‑fluorophenyl)‑8‑phenylquinoline